Top Markets
Coin of the day
Sunshine Biopharma, Inc. Sunshine Biopharma, Inc.

Sunshine Biopharma, Inc.

SBFM
Classement en actions #39262
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of... Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.
Prix de l'action
$1.16
Dernière synchronisation: 2026-07-31
Capitalisation boursière
$580.69K
Changement (1 jour)
-5.69%
Changement (1 an)
-92.32%
Pays
US
Échange Sunshine Biopharma, Inc. (SBFM)

Catégorie

Historique des divisions d’actions pour Sunshine Biopharma, Inc. (SBFM)
L’action Sunshine Biopharma, Inc. (symbole : SBFM) a subi un total de 0 divisions.
La division la plus récente a eu lieu le Aug 14, 2026.
Une action SBFM achetée avant le Aug 14, 2026 équivaudrait aujourd’hui à 0 actions SBFM.
Liste des divisions d’actions
Année Division Multiplicateur Multiplicateur cumulatif
Pas assez de données pour les dates fournies.
Divisions d’actions d’entreprises similaires ou concurrentes